<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560182</url>
  </required_header>
  <id_info>
    <org_study_id>201222</org_study_id>
    <secondary_id>Eudract 2009-017349-77</secondary_id>
    <nct_id>NCT01560182</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Metachromatic Leukodystrophy (MLD)</brief_title>
  <official_title>A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Treatment of Metachromatic Leukodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orchard Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orchard Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I/II clinical trial consists of the application of lentiviral vector-based gene
      therapy to patients affected by Metachromatic Leukodystrophy (MLD), a rare inherited
      Lysosomal Storage Disorder (LSD) resulting from mutations in the gene encoding the
      Arylsulfatase A (ARSA) enzyme. The medicinal product consists of autologous CD34+
      hematopoietic stem/progenitor cells in which a functional ARSA cDNA is introduced by means of
      3rd generation VSV-G pseudotyped lentiviral vectors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 9, 2010</start_date>
  <completion_date type="Anticipated">April 9, 2023</completion_date>
  <primary_completion_date type="Actual">April 9, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of GMFM score</measure>
    <time_frame>24 months after treatment</time_frame>
    <description>An improvement of 10% of the total GMFM score in treated patients, when compared to the the GMFM scores in the historical control MLD population, evaluated 24 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase of residual ARSA activity</measure>
    <time_frame>24 months after treatment</time_frame>
    <description>A significant (≥2 SD) increase of residual ARSA activity as compared to pre- treatment values, measured in PBMC and/or BM progenitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conditioning regimen-related safety</measure>
    <time_frame>at +60 days after transplantation</time_frame>
    <description>The absence of engraftment failure or delayed hematopoietic reconstitution (prolonged aplasia), defined as Absolute Neutrophil Count (ANC)&lt;500/µl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conditioning regimen-related toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>The absence of regimen related toxicity, as determined by a surveillance of clinical (NCI ≥2) and laboratory (NCI ≥3) parameters that will be applied in the short- and long-term follow-up of the treated patients in order to assess the degree of morbidity associated to the conditioning regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The short-term safety and tolerability of lentiviral-transduced cell infusion</measure>
    <time_frame>48 hours after transplant</time_frame>
    <description>It will be evaluated evaluated on the basis of adverse events reporting and monitoring of the systemic reactions to cell infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The long-term safety of lentiviral-transduced cell infusion</measure>
    <time_frame>24 months after the treatment</time_frame>
    <description>Absence of Replication Competent Lentivirus (RCL): ELISA for HIV p24 antigen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The absence of immune responses against the transgene</measure>
    <time_frame>every three months for the first year, then once a year.</time_frame>
    <description>Even if we do not expect immune responses against the functional ARSA enzyme,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the NCV Index for ENG and in the total score for MR</measure>
    <time_frame>24 months after treatment</time_frame>
    <description>An improvement in the NCV Index for ENG and in the total score for MR of ≥ 2 SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transduced cell engraftment</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>Transduced cell engraftment above 4% in PBMCs and CD34+ progenitors in BM. Vector copy number (VCN) per cell in total PBMC, total BM, and peripheral blood (PB) and BM cell subpopulations will also be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IQ measurement above 55</measure>
    <time_frame>24, 30 and 36 months after treatment</time_frame>
    <description>The measurement of an IQ above 55 (threshold for severe disability) at neuro-psychological testings</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lysosomal Storage Disease</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <arm_group>
    <arm_group_label>OTL-200 Gene Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD34+ cells transduced ex vivo with lentiviral vector encoding ARSA cDNA</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>OTL-200 Gene Therapy</intervention_name>
    <description>Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA</description>
    <arm_group_label>OTL-200 Gene Therapy</arm_group_label>
    <other_name>Previously GSK2696274</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-symptomatic MLD patients with the late infantile variant;

          -  Pre- or early-symptomatic MLD patients with the early juvenile variant;

          -  Patients for whom parental/guardian signed informed consent has been obtained.

        Exclusion Criteria:

          -  HIV RNA and/or HCV RNA and/or HBV DNA positive patients

          -  Patients affected by neoplastic diseases

          -  Patients with cytogenetic alterations typical of MDS/AML

          -  Patients with end-organ functions or any other severe disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study

          -  Patients enrolled in other trials.

          -  Patient who underwent allogeneic hematopoietic stem cell transplantation in the
             previous six months.

          -  Patient who underwent allogenic hematopoietic stem cell transplantation with evidence
             of residual cells of donor origin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orchard Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Orchard Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Biffi A, Capotondo A, Fasano S, del Carro U, Marchesini S, Azuma H, Malaguti MC, Amadio S, Brambilla R, Grompe M, Bordignon C, Quattrini A, Naldini L. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J Clin Invest. 2006 Nov;116(11):3070-82.</citation>
    <PMID>17080200</PMID>
  </reference>
  <reference>
    <citation>Biffi A, Cesani M, Fumagalli F, Del Carro U, Baldoli C, Canale S, Gerevini S, Amadio S, Falautano M, Rovelli A, Comi G, Roncarolo MG, Sessa M. Metachromatic leukodystrophy - mutation analysis provides further evidence of genotype-phenotype correlation. Clin Genet. 2008 Oct;74(4):349-57. doi: 10.1111/j.1399-0004.2008.01058.x. Epub 2008 Sep 11.</citation>
    <PMID>18786133</PMID>
  </reference>
  <reference>
    <citation>Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013 Aug 23;341(6148):1233158. doi: 10.1126/science.1233158. Epub 2013 Jul 11.</citation>
    <PMID>23845948</PMID>
  </reference>
  <reference>
    <citation>Biffi A, De Palma M, Quattrini A, Del Carro U, Amadio S, Visigalli I, Sessa M, Fasano S, Brambilla R, Marchesini S, Bordignon C, Naldini L. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest. 2004 Apr;113(8):1118-29.</citation>
    <PMID>15085191</PMID>
  </reference>
  <reference>
    <citation>Capotondo A, Cesani M, Pepe S, Fasano S, Gregori S, Tononi L, Venneri MA, Brambilla R, Quattrini A, Ballabio A, Cosma MP, Naldini L, Biffi A. Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. Hum Gene Ther. 2007 Sep;18(9):821-36.</citation>
    <PMID>17845130</PMID>
  </reference>
  <reference>
    <citation>Cesani M, Capotondo A, Plati T, Sergi LS, Fumagalli F, Roncarolo MG, Naldini L, Comi G, Sessa M, Biffi A. Characterization of new arylsulfatase A gene mutations reinforces genotype-phenotype correlation in metachromatic leukodystrophy. Hum Mutat. 2009 Oct;30(10):E936-45. doi: 10.1002/humu.21093.</citation>
    <PMID>19606494</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OTL-200</keyword>
  <keyword>Metachromatic Leukodystrophy</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>MLD</keyword>
  <keyword>Previously GSK2696274</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

